A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis

BMC Medicine

Volumn 12, Issue 1, 2014, Pages

  Devillier, Philippe ^a,b   Dreyfus, Jean François ^b   Demoly, Pascal ^c,d   Calderón, Moisés A ^e  

^a UPRES EA 220   (France)

^b FOCH HOSPITAL   (France)

^c INSERM   (France)

^d INSTITUT PIERRE LOUIS D EPIDÉMIOLOGIE ET DE SANTÉ PUBLIQUE   (France)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Allergen immunotherapy; Effect size; Grass; Pharmacotherapy; Pollen; Rhinoconjunctivitis

Indexed keywords

AZELASTINE PLUS FLUTICASONE PROPIONATE; BILASTINE; CETIRIZINE; CORTICOSTEROID; DESLORATADINE; FEXOFENADINE; GRASS POLLEN EXTRACT; HISTAMINE H1 RECEPTOR ANTAGONIST; LORATADINE; MONTELUKAST; MP 2902; PLACEBO; UNCLASSIFIED DRUG; ACETIC ACID DERIVATIVE; ALLERGEN; ANDROSTANE DERIVATIVE; DRUG COMBINATION; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MP29-02; PHTHALAZINE DERIVATIVE; QUINOLINE DERIVATIVE;

ARTICLE; DRUG EFFICACY; GRASS POLLEN; HAY FEVER; HUMAN; META ANALYSIS; NASAL PRURITUS; NOSE OBSTRUCTION; RHINORRHEA; SNEEZING; SUBLINGUAL IMMUNOTHERAPY; SYMPTOM; TREATMENT RESPONSE; ADOLESCENT; ADULT; CHILD; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; IMMUNOLOGY; POLLEN; PROCEDURES; RHINITIS, ALLERGIC, SEASONAL; SEASON; SUBLINGUAL DRUG ADMINISTRATION;

ACETATES; ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ALLERGENS; ANDROSTADIENES; CHILD; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION, IMMUNOLOGIC; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LEUKOTRIENE ANTAGONISTS; PHTHALAZINES; POLLEN; QUINOLINES; RHINITIS, ALLERGIC, SEASONAL; SEASONS; SUBLINGUAL IMMUNOTHERAPY;

EID: 84900396041     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-12-71     Document Type: Article

References (76)

1. Bousquet J, Van CP, Khaltaev N, . ARIA Workshop Group, World Health Organization Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001, 108:S147-S334. 10.1067/mai.2001.118891, 11707753, ARIA Workshop Group, World Health Organization.
2. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C, Agache I, Aït-Khaled N, Bachert C, Blaiss MS, Bonini S, Boulet LP, Bousquet PJ, Camargos P, Carlsen KH, Chen Y, Custovic A, Dahl R, Demoly P, Douagui H, Durham SR, van Wijk RG, Kalayci O, Kaliner MA, Kim YY, Kowalski ML, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy 2008, 2008:S8-S160.
3. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, van Wijk RG, Ohta K, Zuberbier T, Schünemann HJ. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010, 126:466-476. 10.1016/j.jaci.2010.06.047, 20816182.
4. Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, Nelson H, Akdis CA. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol 2013, 131:1288-1296. 10.1016/j.jaci.2013.01.049, 23498595.
5. Léger D, Annesi-Maesano I, Carat F, Rugina M, Chanal I, Pribil C, El Hasnaoui A, Bousquet J. Allergic rhinitis and its consequences on quality of sleep: An unexplored area. Arch Intern Med 2006, 166:1744-1748. 10.1001/archinte.166.16.1744, 16983053.
6. Hankin CS, Cox L, Lang D, Bronstone A, Fass P, Leatherman B, Wang Z. Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study. Ann Allergy Asthma Immunol 2010, 104:79-85. 10.1016/j.anai.2009.11.010, 20143650.
7. Meltzer EO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol 2001, 108:S45-S53. 10.1067/mai.2001.115566, 11449206.
8. Blaiss MS. Allergic rhinoconjunctivitis: burden of disease. Allergy Asthma Proc 2007, 28:393-397. 10.2500/aap.2007.28.3013, 17883905.
9. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc 2007, 28:3-9. 10.2500/aap.2007.28.2934, 17390749.
10. Meltzer EO, Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol 2011, 106:S12-S16. 10.1016/j.anai.2010.10.014, 21277528.
11. Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, Lang DM, Nicklas RA, Oppenheimer J, Portnoy JM, Randolph CC, Schuller D, Spector SL, Tilles SA, . Joint Task Force on Practice, American Academy of Allergy, Asthma & Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol Aug 2008, 122:S1-S84. Joint Task Force on Practice, American Academy of Allergy, Asthma & Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology.
12. van Cauwenberge P, Bachert C, Passalacqua G, Bousquet J, Canonica GW, Durham SR, Fokkens WJ, Howarth PH, Lund V, Malling HJ, Mygind N, Passali D, Scadding GK, Wang DY. Consensus statement on the treatment of allergic rhinitis, European Academy of Allergology and Clinical Immunology. Allergy 2000, 55:116-134. 10.1034/j.1398-9995.2000.00526.x, 10726726.
13. Calderon MA, Demoly P, Gerth Van Wijk R, Bousquet J, Sheikh A, Frew A, Scadding G, Bachert C, Malling HJ, Valenta R, Bilo B, Nieto A, Akdis C, Just J, Vidal C, Varga EM, Alvarez-Cuesta E, Bohle B, Bufe A, Canonica WG, Cardona V, Dahl R, Didier A, Durham SR, Eng P, Fernandez-Rivas M, Jacobsen L, Jutel M, Kleine-Tebbe J, Klimek L. EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clin Transl Allergy 2012, 2:20. 10.1186/2045-7022-2-20, 3514324, 23110958.
14. Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006, 117:1021-1035. 10.1016/j.jaci.2006.02.040, 16675328.
15. Canonica GW, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Pawankar R, Potter PC, Bousquet PJ, Cox LS, Durham SR, Nelson HS, Passalacqua G, Ryan DP, Brozek JL, Compalati E, Dahl R, Delgado L, van Wijk RG, Gower RG, Ledford DK, Filho NR, Valovirta EJ, Yusuf OM, Zuberbier T, Akhanda W, Almarales RC, Ansotegui I, Bonifazi F, Ceuppens J, Chivato T, et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009, 64:1-59.
16. Nelson HS, Nolte H, Creticos P, Maloney J, Wu J, Bernstein DI. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol 2011, 127:72-80. 10.1016/j.jaci.2010.11.035, 21211643.
17. Blaiss M, Maloney J, Nolte H, Gawchik S, Yao R, Skoner DP. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 2011, 127:64-71. 10.1016/j.jaci.2010.11.034, 21211642.
18. Durham SR, Emminger W, Kapp A, Colombo G, de Monchy JG, Rak S, Scadding GK, Andersen JS, Riis B, Dahl R. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010, 125:131-138. 10.1016/j.jaci.2009.10.035, 20109743.
19. Didier A, Worm M, Horak F, Sussman G, de Beaumont O, Le Gall M, Melac M, Malling HJ. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 2011, 128:559-566. 10.1016/j.jaci.2011.06.022, 21802126.
20. Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, Emminger W, Rivas MF, Ribel M, Durham SR. Efficacy and safety of sublingual immunotherapy with grass allergen tablet for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006, 118:434-440. 10.1016/j.jaci.2006.05.003, 16890769.
21. Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 2011, 66:740-752. 10.1111/j.1398-9995.2011.02583.x, 21443635.
22. Di Bona D, Plaia A, Scafidi V, Leto-Barone MS, Di Lorenzo G. Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis. J Allergy Clin Immunol 2010, 126:558-566. 10.1016/j.jaci.2010.06.013, 20674964.
23. Matricardi PM, Kuna P, Panetta V, Wahn U, Narkus A. Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: a comparison based on meta-analyses. J Allergy Clin Immunol 2011, 128:791-799. 10.1016/j.jaci.2011.03.049, 21620452.
24. Turner RM, Bird SM, Higgins JP. The impact of study size on meta-analyses: examination of underpowered studies in Cochrane reviews. PLoS One 2013, 8:e59202. 10.1371/journal.pone.0059202, 3609745, 23544056.
25. Stanley TD, Stephen B, Jarrell SB, Doucouliagos H. Could it be better to discard 90% of the data? A statistical paradox. Am Stat 2010, 64:70-77.
26. Kraemer HC, Gardner C, Brooks JO, Yesavage JA. Advantages of excluding underpowered studies in meta-analysis: inclusionist versus exclusionist viewpoints. Psychol Methods 1998, 3:23-31.
27. Grouin JM, Vicaut E, Jean-Alphonse S, Demoly P, Wahn U, Didier A, de Beaumont O, Montagut A, Le Gall M, Devillier P. The average Adjusted Symptom Score, a new primary efficacy endpoint for specific immunotherapy clinical trial. Clin Exp Allergy 2011, 41:1282-1288. 10.1111/j.1365-2222.2011.03700.x, 21375606.
28. Meta-Analysis Made Easy with MIX 2.0. [http://www.meta-analysis-made-easy.com/].
29. Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ, Passalacqua G, Potter P, Valovirta E. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007, 62:317-324. 10.1111/j.1398-9995.2006.01312.x, 17298350.
30. Meltzer EO, Prenner BM, Nayak A. Efficacy and tolerability of once-daily 5 mg desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis: assessment during the spring and fall allergy seasons. Clin Drug Invest 2001, 21:25-32.
31. Berger WE, Schenkel EJ, Mansfield LE, . Desloratadine Study Group Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann Allergy Asthma Immunol 2002, 89:485-491. 10.1016/S1081-1206(10)62086-8, 12452207, Desloratadine Study Group.
32. Raphael GD, Angello JT, Wu MM, Druce HM. Efficacy of diphenhydramine vs desloratadine and placebo in patients with moderate-to-severe seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2006, 96:606-614. 10.1016/S1081-1206(10)63557-0, 16680933.
33. Pradalier A, Neukirch C, Dreyfus I, Devillier P. Desloratadine improves quality of life and symptom severity in patients with allergic rhinitis. Allergy 2007, 62:1331-1334. 10.1111/j.1398-9995.2007.01374.x, 17521311.
34. Bachert C, Kuna P, Sanquer F, Ivan P, Dimitrov V, Gorina MM, van de Heyning P, Loureiro A, . Bilastine International Working Group Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 2009, 64:158-165. 10.1111/j.1398-9995.2008.01813.x, 19132976, Bilastine International Working Group.
35. Kuna P, Bachert C, Nowacki Z, van Cauwenberge P, Agache I, Fouquert L, Roger A, Sologuren A, Valiente R, . Bilastine International Working Group Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy 2009, 39:1338-1347. 10.1111/j.1365-2222.2009.03257.x, 19438584, Bilastine International Working Group.
36. Leynadier F. Efficacy and safety of levocetirizine in seasonal allergic rhinitis. Acta Otorhinolaryngol Belg 2001, 55:305-312.
37. Segall N, Gawchik S, Georges G, Haeusler JM. Efficacy and safety of levocetirizine in improving symptoms and health-related quality of life in US adults with seasonal allergic rhinitis: a randomized, placebo-controlled study. Ann Allergy Asthma Immunol 2010, 104:259-267. 10.1016/j.anai.2009.12.003, 20377116.
38. Nayak AS, Philip G, Lu S, Malice MP, Reiss TF, . Montelukast Fall Rhinitis Investigator Group Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 2002, 88:592-600. 10.1016/S1081-1206(10)61891-1, 12086367, Montelukast Fall Rhinitis Investigator Group.
39. Philip G, Malmstrom K, Hampel FC, Weinstein SF, LaForce CF, Ratner PH, Malice MP, Reiss TF, . Montelukast Spring Rhinitis Study Group Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002, 32:1020-1028. 10.1046/j.1365-2222.2002.01422.x, 12100048, Montelukast Spring Rhinitis Study Group.
40. van Adelsberg J, Philip G, LaForce CF, Weinstein SF, Menten J, Malice MP, Reiss TF, . Montelukast Spring Rhinitis Investigator Group Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003, 90:214-222. 10.1016/S1081-1206(10)62144-8, 12602669, Montelukast Spring Rhinitis Investigator Group.
41. van Adelsberg J, Philip G, Pedinoff AJ, Meltzer EO, Ratner PH, Menten J, Reiss TF, . Montelukast Fall Rhinitis Study Group Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy 2003, 58:1268-1276. 10.1046/j.1398-9995.2003.00261.x, 14616102, Montelukast Fall Rhinitis Study Group.
42. Anolik R, . Mometasone Furoate Nasal Spray With Loratadine Study Group Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2008, 100:264-271. 10.1016/S1081-1206(10)60452-8, 18426147, Mometasone Furoate Nasal Spray With Loratadine Study Group.
43. Bernstein DI, Schoenwetter WF, Nathan RA, Storms W, Ahlbrandt R, Mason J. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997, 79:443-448. 10.1016/S1081-1206(10)63041-4, 9396979.
44. Howarth PH, Stern MA, Roi L, Reynolds R, Bousquet J. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999, 104:927-929. 10.1016/S0091-6749(99)70070-9, 10550734.
45. Casale TB, Andrade C, Qu R. Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis. Allergy Asthma Proc 1999, 20:193-198. 10.2500/108854199778553046, 10389553.
46. Wahn U, Meltzer EO, Finn AF, Kowalski ML, Decosta P, Hedlin G, Scheinmann P, Bachert C, Rosado Pinto JE, Baena-Cagnani C, Potter P, Simons FE, Ruuth E. Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis. J Allergy Clin Immunol 2003, 111:763-769. 10.1067/mai.2003.1384, 12704355.
47. Berger WE, White MV, . Rhinitis Study Group Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine. Ann Allergy Asthma Immunol 2003, 91:205-211. 10.1016/S1081-1206(10)62179-5, 12952117, Rhinitis Study Group.
48. LaForce CF, Corren J, Wheeler WJ, Berger WE, . Rhinitis Study Group Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine. Ann Allergy Asthma Immunol 2004, 93:154-159. 10.1016/S1081-1206(10)61468-8, 15328675, Rhinitis Study Group.
49. Lumry W, Prenner B, Corren J, Wheeler W. Efficacy and safety of azelastine nasal spray at a dose of 1 spray per nostril twice daily. Ann Allergy Asthma Immunol 2007, 99:267-272. 10.1016/S1081-1206(10)60663-1, 17910331.
50. Graft D, Aaronson D, Chervinsky P, Kaiser H, Melamed J, Pedinoff A, Rosen JP, Schenkel EJ, Vandewalker ML, Keim A, Jensen PK, Nolop K, Mesarina-Wicki B. A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray. J Allergy Clin Immunol 1996, 98:724-731. 10.1016/S0091-6749(96)70119-7, 8876546.
51. Hebert JR, Nolop K, Lutsky BN. Once-daily mometasone furoate aqueous nasal spray (Nasonex) in seasonal allergic rhinitis: an active- and placebo-controlled study. Allergy 1996, 51:569-576.
52. Gawchik S, Goldstein S, Prenner B, John A. Relief of cough and nasal symptoms associated with allergic rhinitis by mometasone furoate nasal spray. Ann Allergy Asthma Immunol 2003, 90:416-421. 10.1016/S1081-1206(10)61826-1, 12722964.
53. Prenner BM, Lanier BQ, Bernstein DI, Shekar T, Teper A. Mometasone furoate nasal spray reduces the ocular symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2010, 125:1247-1253. 10.1016/j.jaci.2010.03.004, 20434199.
54. Martin BG, Ratner PH, Hampel FC, Andrews CP, Toler T, Wu W, Faris MA, Philpot EE. Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents. Allergy Asthma Proc 2007, 28:216-225. 10.2500/aap.2007.28.2983, 17479608.
55. Kaiser HB, Naclerio RM, Given J, Toler TN, Ellsworth A, Philpot EE. Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2007, 119:1430-1437. 10.1016/j.jaci.2007.02.022, 17418384.
56. Ratner PH, Wingertzahn MA, van Bavel JH, Hampel F, Darken PF, Shah T. Efficacy and safety of ciclesonide nasal spray for the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2006, 118:1142-1148. 10.1016/j.jaci.2006.07.050, 17088141.
57. Carr W, Bernstein J, Lieberman P, Meltzer E, Bachert C, Price D, Munzel U, Bousquet J. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 2012, 129:1282-1289. 10.1016/j.jaci.2012.01.077, 22418065.
58. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006, 117:802-809. 10.1016/j.jaci.2005.12.1358, 16630937.
59. Didier A, Malling HJ, Worm M, Horak F, Jäger S, Montagut A, André C, de Beaumont O, Melac M. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007, 120:1338-1345. 10.1016/j.jaci.2007.07.046, 17935764.
60. Wahn U, Tabar A, Kuna P, Halken S, Montagut A, de Beaumont O, Le Gall M, . SLIT Study Group Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009, 123:160-166. 10.1016/j.jaci.2008.10.009, 19046761, SLIT Study Group.
61. Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L, Knecht R, Stephan V, Tholstrup B, Weisshaar C, Kaiser F. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009, 123:167-173. 10.1016/j.jaci.2008.10.044, 19130937.
62. Cox LS, Casale TB, Nayak AS, Bernstein DI, Creticos PS, Ambroisine L, Melac M, Zeldin RK. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE. J Allergy Clin Immunol 2012, 130:1327-1334. 10.1016/j.jaci.2012.08.032, 23122534.
63. Murphy K, Gawchik S, Bernstein D, Andersen J, Rud PM. A phase 3 trial assessing the efficacy and safety of grass allergy immunotherapy tablet in subjects with grass pollen-induced allergic rhinitis with or without conjunctivitis, with or without asthma. J Negat Results Biomed 2013, 12:10. 10.1186/1477-5751-12-10, 3689082, 23725348.
64. Horak F, Ziegelmeyer P, Ziegelmayer R, Lemell P, Devillier P. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol 2009, 124:471-477. 10.1016/j.jaci.2009.06.006, 19647862.
65. Compalati E, Baena-Cagnani R, Penagos M, Badellino H, Braido F, Gómez RM, Canonica GW, Baena-Cagnani CE. Systematic review on the efficacy of fexofenadine in seasonal allergic rhinitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Int Arch Allergy Immunol 2011, 156:1-15. 10.1159/000321896, 21969990.
66. Mösges R, König V, Köberlein J. The effectiveness of levocetirizine in comparison with loratadine in treatment of allergic rhinitis - a meta-analysis. Allergol Int 2011, 60:541-546. 10.2332/allergolint.10-OA-0300, 21918368.
67. Compalati E, Canonica GW. Efficacy and safety of rupatadine for allergic rhino-conjunctivitis: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis. Curr Med Res Opin 2013, 29:1539-1551. 10.1185/03007995.2013.822855, 23826741.
68. Rodrigo GJ, Yañez A. The role of antileukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials. Ann Allergy Asthma Immunol 2006, 96:779-786. 10.1016/S1081-1206(10)61339-7, 16802764.
69. Wilson AM, O'Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med 2004, 116:338-344. 10.1016/j.amjmed.2003.10.030, 14984820.
70. Benninger M, Farrar JR, Blaiss M, Chipps B, Ferguson B, Krouse J, Marple B, Storms W, Kaliner M. Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class. Ann Allergy Asthma Immunol 2010, 104:13-29. 10.1016/j.anai.2009.11.020, 20143641.
71. Schäfer T, Schnoor M, Wagenmann M, Klimek L, Bachert C. Therapeutic Index (TIX) for intranasal corticosteroids in the treatment of allergic rhinitis. Rhinology 2011, 49:272-280.
72. Mösges R, König V, Köberlein J. The effectiveness of modern antihistamines for treatment of allergic rhinitis - an IPD meta-analysis of 140,853 patients. Allergol Int 2013, 62:215-222. full_text, 23524648.
73. Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. Draft CHMP/EWP/18504/2006 2008, London, UK: Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMEA), Available at http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500003605 (Accessed on 29 April 2014).
74. Howarth P, Malling HJ, Molimard M, Devillier P. Analysis of allergen immunotherapy studies shows increased clinical efficacy in highly symptomatic patients. Allergy 2012, 67:321-327. 10.1111/j.1398-9995.2011.02759.x, 22142377.
75. Durham S, Birk AO, Andersen JS. Days with severe symptoms: an additional efficacy endpoint in immunotherapy trials. Allergy 2011, 66:120-123. 10.1111/j.1398-9995.2010.02434.x, 20608918.
76. Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK, Wurtzen PA, Andersen JS, Tholstrup B, Riis B, Dahl R. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012, 129:717-725. 10.1016/j.jaci.2011.12.973, 22285278.